BioCentury
ARTICLE | Financial News

Immunex beats consensus EPS

January 24, 2001 8:00 AM UTC

IMNX reported fourth quarter and fiscal year EPS of $0.09 and $0.28, respectively, beating by a penny the consensus EPS estimates for both. Sales of IMNX's Enbrel etanercept soluble TNF receptor to tr...